On the stock market since 2024, it operates in the world of health and science. It has 96 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Executives buying with their own money is usually read as confidence in the company’s future.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
The price is looking for direction — no strong breakout, no collapse.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
Business Quality: Profit power and business quality trail similar companies in the sector.
The stock trades 31% below its peak. The market has trimmed its expectations for the company.
Over the last 12 months, company executives reported 37 buys and 32 sells. Management buying with its own money is usually read as a good sign.
The average analyst price target is $37.50 — 245% above today’s price.
A loss of $83.9M against $0 in annual sales. And on top of that, sales fell from the year before.
This stock swings about 2.2 times as much as the market average. Big rallies — and big drops — can both happen fast.
At the current pace of spending, the cash lasts about 1.3 years. After that, the company needs to find new money.
On our five-subject report card, ARTV sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: ARTV is a high-risk stock — not yet profitable, and its future rides on its product catching on.
Analysts’ average target sits above today’s price, yet the valuation grade (27/100) says the stock isn’t cheap.